세계 소아용 의약품 시장 : 조사 보고서 - 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Pediatric Medicines Market is presumed to reach the market size of nearly USD 8.87 Billion by 2032 from USD 5.22 Billion in 2023 with a CAGR of 6.07% under the study period 2024 - 2032.

Pediatric medicines are pharmaceutical formulations specifically designed and formulated for treating children and infants. These medicines consider age, weight, and developmental stages to ensure safety and effectiveness. Pediatric formulations may include liquids, chewable tablets, or specially coated pills to facilitate administration. The development of pediatric medicines is crucial for addressing the unique healthcare needs of children, providing accurate dosages and palatable formulations to enhance compliance and overall therapeutic outcomes.

MARKET DYNAMICS

The increasing focus on child healthcare and the growing awareness of pediatric-specific medical needs drives the pediatric medicines market. Factors such as rising pediatric populations, advancements in pediatric medicine formulations, and initiatives to address unmet medical needs in children contribute to market growth. Regulatory incentives for pediatric drug development and expanding pediatric clinical trials also significantly drive innovation in pediatric medicines. Additionally, the prevalence of chronic diseases in children and the demand for age-appropriate formulations and dosage forms boost the pediatric medicines market. The need for safe and effective medications for various pediatric conditions, including infections, respiratory disorders, and neurodevelopmental disorders, further propels research and development activities in the pediatric healthcare sector.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pediatric medicines. The growth and trends of pediatric medicines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the pediatric medicines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type Of Medicine

• Respiratory Disorder Medicine
• Autoimmune Disorder Medicine
• Cardiovascular Medicine
• Gastrointestinal Medicines

By Type Of Disease

• Respiratory Diseases
• Infectious Diseases
• Cns Diseases
• Gastrointestinal Diseases
• Oncological Diseases
• Others

By Route Of Administration

• Oral
• Topical
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pediatric Medicines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pediatric Medicines market include Novartis AG, GlaxoSmithKline, Pfizer Inc., Merck & Co., AstraZeneca, Johnson & Johnson, Sanofi, Roche Holding AG, Teva Pharmaceutical Industries, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim, Bristol-Myers Squibb, AbbVie Inc., and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PEDIATRIC MEDICINES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type of Medicine
  • 3.7.2 Market Attractiveness Analysis By Type of Disease
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PEDIATRIC MEDICINES MARKET ANALYSIS BY TYPE OF MEDICINE

• 5.1 Overview by Type of Medicine
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type of Medicine
• 5.4 Respiratory Disorder Medicine Historic and Forecast Sales by Regions
• 5.5 Autoimmune Disorder Medicine Historic and Forecast Sales by Regions
• 5.6 Cardiovascular Medicine Historic and Forecast Sales by Regions
• 5.7 Gastrointestinal Medicines Historic and Forecast Sales by Regions

6 . GLOBAL PEDIATRIC MEDICINES MARKET ANALYSIS BY TYPE OF DISEASE

• 6.1 Overview by Type of Disease
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Type of Disease
• 6.4 Respiratory Diseases Historic and Forecast Sales by Regions
• 6.5 Infectious Diseases Historic and Forecast Sales by Regions
• 6.6 CNS Diseases Historic and Forecast Sales by Regions
• 6.7 Gastrointestinal Diseases Historic and Forecast Sales by Regions
• 6.8 Oncological Diseases Historic and Forecast Sales by Regions
• 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL PEDIATRIC MEDICINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1 Overview by Route of Administration
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Route of Administration
• 7.4 Oral Historic and Forecast Sales by Regions
• 7.5 Topical Historic and Forecast Sales by Regions
• 7.6 Parenteral Historic and Forecast Sales by Regions
• 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL PEDIATRIC MEDICINES MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1 Overview by Distribution Channel
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Distribution Channel
• 8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 8.6 Online Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL PEDIATRIC MEDICINES MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. South East Asia Sales Analysis
  • 9.5.10. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PEDIATRIC MEDICINES COMPANIES

• 10.1. Pediatric Medicines Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF PEDIATRIC MEDICINES INDUSTRY

• 11.1. Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Novartis AG
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. GlaxoSmithKline
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Pfizer Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Merck & Co.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. AstraZeneca
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. Johnson & Johnson
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Sanofi
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Roche Holding AG
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Teva Pharmaceutical Industries
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Eli Lilly and Company
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments
• 11.13. Novo Nordisk A/S
  • 11.13.1. Company Overview
  • 11.13.2. Company Revenue
  • 11.13.3. Products
  • 11.13.4. Recent Developments
• 11.14. Boehringer Ingelheim
  • 11.14.1. Company Overview
  • 11.14.2. Company Revenue
  • 11.14.3. Products
  • 11.14.4. Recent Developments
• 11.15. Bristol-Myers Squibb
  • 11.15.1. Company Overview
  • 11.15.2. Company Revenue
  • 11.15.3. Products
  • 11.15.4. Recent Developments
• 11.16. AbbVie Inc.
  • 11.16.1. Company Overview
  • 11.16.2. Company Revenue
  • 11.16.3. Products
  • 11.16.4. Recent Developments
• 11.17. Others.
  • 11.17.1. Company Overview
  • 11.17.2. Company Revenue
  • 11.17.3. Products
  • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies